CHRS Coherus BioSciences, Inc.

21.85
-1  -3%
Previous Close 22.55
Open 22.50
Price To book 50.33
Market Cap 1.12B
Shares 51,147,000
Volume 195,919
Short Ratio 6.95
Av. Daily Volume 479,162

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 data released January 2016. Endpoints met. However, commercialization not possible in US before 2029 due to patent issues
CHS-0214
Rheumatoid arthritis
Phase 2b data released June 2016
CHS-131
Relapsing remitting multiple sclerosis (RRMS)
Phase 3 trial met endpoint November 2015. However, commercialization not possible in US before 2029 due to patent issues
CHS-0214
Psoriasis
Phase 3 top-line data met endpoints August 2016. Full data due released January 10, 2016. BLA filing due 1H 2017.
CHS-1420
Psoriasis
PDUFA date June 9, 2017.
CHS-1701
Pegfilgrastim biosimilar

Latest News

  1. Coherus BioSciences, Inc. :CHRS-US: Earnings Analysis: Q4, 2016 By the Numbers : March 20, 2017
  2. COHERUS BIOSCIENCES, INC. Financials
  3. Coherus BioSciences, Inc. :CHRS-US: Earnings Analysis: 2016 By the Numbers : March 16, 2017
  4. COHERUS BIOSCIENCES, INC. Files SEC form 10-K, Annual Report
  5. Edited Transcript of CHRS earnings conference call or presentation 13-Mar-17 8:30pm GMT
  6. Coherus BioSciences Inc Earnings Call scheduled for 4:30 pm ET today
  7. Coherus BioSciences reports 4Q loss
  8. Coherus BioSciences reports 4Q loss
  9. COHERUS BIOSCIENCES, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and
  10. Coherus BioSciences Reports Fourth Quarter and Full Year 2016 Corporate Highlights and Financial Results
  11. Q4 2016 Coherus BioSciences Inc Earnings Release - After Market Close
  12. COHERUS BIOSCIENCES, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
  13. Coherus Addresses Trade Secret Action Filed by Amgen
  14. COHERUS BIOSCIENCES, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
  15. Statement by Coherus CEO Regarding Biosimilars User Fees
  16. 5 Small-Cap Biotech Stocks to Buy in March
  17. Coherus Announces CHS-1420 Pharmacokinetic Clinical Bioequivalence Study Meets Primary Endpoint
  18. Coherus BioSciences Management to Present at Two Investor Healthcare Conferences in March
  19. Coherus BioSciences to Report Fourth Quarter and Full Year 2016 Financial Results on March 13th
  20. Coherus BioSciences Announces New Employment Inducement Grants